| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000278 | Mitotic cell cycle | Decreases phenotype | PMID:15099639 |
| GO:0001516 | Prostaglandin biosynthetic process | Increases phenotype | PMID:31048000 |
| GO:0001776 | Leukocyte homeostasis | Decreases phenotype | PMID:32289289 |
| GO:0002027 | Regulation of heart rate | Increases phenotype | PMID:11545620 |
| GO:0002693 | Positive regulation of cellular extravasation | Increases phenotype | PMID:32289289 |
| GO:0004784 | Superoxide dismutase activity | Decreases phenotype | PMID:36346500 |
| GO:0006309 | Apoptotic dna fragmentation | Increases phenotype | PMID:11583291 |
| GO:0006693 | Prostaglandin metabolic process | Affects phenotype | PMID:37453669 |
| GO:0006699 | Bile acid biosynthetic process | Affects phenotype | PMID:29222744 |
| GO:0006749 | Glutathione metabolic process | Increases phenotype | PMID:21360558; PMID:26921665 |
| GO:0006874 | Cellular calcium ion homeostasis | Affects phenotype | PMID:34748853 |
| GO:0006915 | Apoptotic process | Affects phenotype | PMID:11583291; PMID:12357301; PMID:15263833; PMID:15670648; PMID:18348186; PMID:19438858 |
| GO:0007033 | Vacuole organization | Increases phenotype | PMID:29222744 |
| GO:0007049 | Cell cycle | Decreases phenotype | PMID:11583291; PMID:12357301; PMID:15670648 |
| GO:0007204 | Positive regulation of cytosolic calcium ion concentration | Increases phenotype | PMID:24333387 |
| GO:0007286 | Spermatid development | Decreases phenotype | PMID:37844793 |
| GO:0007613 | Memory | Affects phenotype | PMID:36346500 |
| GO:0008206 | Bile acid metabolic process | Affects phenotype | PMID:38815664 |
| GO:0008210 | Estrogen metabolic process | Affects phenotype | PMID:37453669 |
| GO:0008217 | Regulation of blood pressure | Affects phenotype | PMID:18622250; PMID:9773140; PMID:8227469 |
| GO:0008219 | Cell death | Increases phenotype | PMID:15099639; PMID:16388830; PMID:29222744 |
| GO:0008283 | Cell population proliferation | Decreases phenotype | PMID:11583291; PMID:15746067; PMID:18348186; PMID:19908241; PMID:29665328 |
| GO:0009636 | Response to toxic substance | Decreases phenotype | PMID:21319177 |
| GO:0010918 | Positive regulation of mitochondrial membrane potential | Decreases phenotype | PMID:26921665 |
| GO:0010942 | Positive regulation of cell death | Increases phenotype | PMID:23799623 |
| GO:0015721 | Bile acid and bile salt transport | Decreases phenotype | PMID:38815664 |
| GO:0032967 | Positive regulation of collagen biosynthetic process | Increases phenotype | PMID:21360558 |
| GO:0034101 | Erythrocyte homeostasis | Decreases phenotype | PMID:32289289 |
| GO:0034440 | Lipid oxidation | Increases phenotype | PMID:21360558 |
| GO:0035812 | Renal sodium excretion | Increases phenotype | PMID:3136271 |
| GO:0040018 | Positive regulation of multicellular organism growth | Increases phenotype | PMID:37844793 |
| GO:0042307 | Positive regulation of protein import into nucleus | Increases phenotype | PMID:21360558 |
| GO:0042311 | Vasodilation | Increases phenotype | PMID:2113882 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:24333387; PMID:37844793 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:34748853 |
| GO:0046466 | Membrane lipid catabolic process | Decreases phenotype | PMID:2116696 |
| GO:0046622 | Positive regulation of organ growth | Increases phenotype | PMID:37844793 |
| GO:0048143 | Astrocyte activation | Increases phenotype | PMID:24333387 |
| GO:0048266 | Behavioral response to pain | Increases phenotype | PMID:32289289 |
| GO:0060209 | Estrus | Affects phenotype | PMID:37453669 |
| GO:0060326 | Cell chemotaxis | Decreases phenotype | PMID:6853143 |
| GO:0072520 | Seminiferous tubule development | Affects phenotype | PMID:37844793 |
| GO:0072593 | Reactive oxygen species metabolic process | Affects phenotype | PMID:34748853 |
| GO:0072719 | Cellular response to cisplatin | Decreases phenotype | PMID:33785417 |
| GO:0090557 | Establishment of endothelial intestinal barrier | Increases phenotype | PMID:34506768 |
| GO:0098532 | Histone h3-k27 trimethylation | Increases phenotype | PMID:29665328 |
| GO:0098743 | Cell aggregation | Increases phenotype | PMID:33785417 |
| GO:1900227 | Positive regulation of nlrp3 inflammasome complex assembly | Increases phenotype | PMID:36088791 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Increases phenotype | PMID:24333387 |
| GO:1904231 | Positive regulation of succinate dehydrogenase activity | Decreases phenotype | PMID:24333387 |
| GO:1905523 | Positive regulation of macrophage migration | Increases phenotype | PMID:36088791 |
| GO:2000242 | Negative regulation of reproductive process | Increases phenotype | PMID:37844793 |
| GO:2001170 | Negative regulation of atp biosynthetic process | Increases phenotype | PMID:33147516 |
| GO:2001171 | Positive regulation of atp biosynthetic process | Decreases phenotype | PMID:26921665 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.